Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients

Antiviral Therapy

Volumn 13, Issue 8, 2008, Pages 1047-1055

  Tural, Cristina ^a   Galeras, Josep Antón ^a   Planas, Ramon ^a   Coll, Susanna ^a   Sirera, Guillem ^a   Giménez, Dolors ^a   Salas, Anna ^a   Rey Joly, Celestino ^a   Círera, Isabel ^a   Mérquez, Carmen ^a   Tor, Jordi ^a   Videla, Sebastia ^a   García Retortillo, Montserrat ^a   Clotet, Bonaventura ^a   Solà, Ricard ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; PEGINTERFERON ALPHA2A; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS RNA;

ADULT; ANEMIA; ARTICLE; ASTHENIA; BODY WEIGHT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTHYROIDISM; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; MALE; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL;

EID: 58149520605     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
2. Hadziyannis SJ, Sette H, Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
3. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450.
4. Carrat F, Bani-Sadr F, Pol S, et al. Pegytated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292:2839-2848.
5. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18:F27-F36.
6. Crespo M, Sauleda S, Esteban JI, et al. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepat 2007; 14:228-238.
7. Ballesteros AL, Franco S, Fuster D, et al. Early HCV dynamics on peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches. AIDS 2004; 18:59-66.
8. Cargnel A, Angeli E, Mainini A, et al. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV coinfected patients on HAART. Antivir Ther 2005; 10:309-317.
9. Chung RT, Andersen J, Volberding P, et al. Peginterferon a1fa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-459.
10. Blackard JT, Komurian-Pradel F, Perret M, et al. Intrahepatic cytokine expression is downregulated during HCV/HIV co-infection. J Med Virol 2006; 78:202-207.
11. + T cells in HIV/HCV versus HCV. Hepatology 2004; 40:125-132.
12. Koziel MJ. Cellular immune responses against hepatitis C virus. Clin Infect Dis 2005; 41 Suppl 1:S25-S31.
13. Netski DM, Mosbruger T, Depla E, et al. Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis 2005; 41:667-675.
14. Graham CS, Wells A, Liu T, et al. Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection. AIDS 2006; 20:345-351.
15. Shire NJ, Horn PS, Rouster SD, et al. HCV Kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1 HCV/HIV coinfected patients with hemophilia. Hepatology 2006; 44:1146-1157.
16. Laskus T, Wilkinson J, Karim R, et al. Hepatitis C virus quasispecies in HIV-infected women: role of injecting drug use an highly active antiretroviral therapy (HAART). Hepatology 2007; 46:359-370.
17. Shuhart MC, Sullivan DG, Bekele K, et al. HIV infection and antiretroviral therapy: effect on hepatitis C virus quasispecies variability. J Infect Dis 2006; 193:1211-1218.
18. Chambers TJ, Fan X, Droll DA, et al. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J Virol 2005; 79:3071-3083.
19. Zeuzem S, Herrmann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120 1438-1447.
20. Yee HS, Currie SL, Darling JM, Wright TL. Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office. Am J Gastroenterol 2006; 101:2360-2378.
21. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289-293.
22. Solà R, Galeras JA, Montoliu S, et al. Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment. AIDS Res Hum Retroviruses 2006; 22:393-400.
23. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-569.
24. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34:283-287.
25. Fuster D, Planas R, Muga R, et al. Advanced liver fibrosis in HIV/ HCV-coinfected patients on antiretroviral therapy. AIDS Res Hum Retroviruses 2004; 20:1293-1297.
26. Dahari H, Markatou M, Zeremski M, et al. Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/ HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol 2007; 47:23-30.
27. Pineda JA, Mira JA, Gil Ide L, et al. Influence of concomitant antiretroviral therapy on the sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. J Antimicrob Chemother 2007; 60:1347-1354.
28. Vispo E, Barreiro P, Pineda JA, et al. Law response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008; 13:429-437.
29. Bani-Sadr F, Denoeud L, Morand P, et al. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? J Acquir Immune Defic Syndr 2007; 45:123-125.
30. Torriani FJ, Ribeiro RM, Gilbert TL, et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV co-infection. J Infect Dis 2003; 188:1498-1507.
31. Talal AH, Shata MT, Markatou M, et al. Virus dynamics and immune responses during treatment in patients coinfected with hepatitis C and HIV. J Acquir Immune Defic Syndr 2004; 35:103-113.
32. Sherman KE, Shire N, Rouster SD, et al. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology 2005; 128:313-327.
33. Banner BF, Barton AL, Cable EE, Smith I, Bonkovsky HL. A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy and chronic hepatitis C. Mod Pathol 1995; 8:232-238.
34. Myers RP, Patel K, Pianko S, Poynard T, McHutchison JG. The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C. J Viral Hepat 2003; 10:16-22.
35. Lindahl K, Stable I, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005; 41:275-279.
36. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21:1073-1089.
37. Thomas DL. Options for treatment of hepatitis C in HIV-infected persons. J Hepatol 2006; 44 Suppl 1:S40-S43.
38. Ramos B, Nunez M, Rendon A, et al. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/ HIV-coinfected patients. J Viral Hepat 2007; 14:387-391.
39. Jacobson IM, Everson GT, Gordon SC, et al. Interim analysis results from a Phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C. 58th Annual Meeting of the American Association for the Study of Liver Diseases. 2-6 November 2007, Boston, MA, USA. Abstract 177.
40. C Hezode, P Ferenci, GM Dusheiko, et al. PROVE2: Phase II study of VX950 (telaprevir) in combination with peginterferon alfa2a with or without ribavirin in subjects with chronic hepatitis C, first interim analysis. 58th Annual Meeting of the American Association for the Study of Liver Diseases. 2-6 November 2007, Boston, MA, USA. Abstract 80.